# PROCEPT BioRobotics Corporation (PRCT) — Investment Analysis

## Company & Research Metadata

- **Company:** PROCEPT BioRobotics Corporation
- **Ticker:** PRCT
- **Exchange:** NASDAQ
- **Sector / Industry:** Health Care / Medical Devices and Surgical Robotics (Urology)
- **Template version:** 2.7
- **Research date:** 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-20)
- **Valuation / score price snapshot:** $20.17 — 2026-11-03 regular-session close, America/New_York
- **Tracking tier:** Primary Watchlist
- **Owned:** No
- **Primary operating period reviewed:** Q2 2026 and H1 2026
- **Historical period reviewed:** FY2023–FY2025 plus H1 2026
- **Latest investor presentation reviewed:** Q2 2026 earnings materials, 2026-08-04; no separate investor presentation reviewed
- **Latest earnings call reviewed:** Q2 2026 earnings call, 2026-08-04
- **Latest post-earnings management commentary reviewed:** September 2026 debt amendment filing; no additional management conference transcript reviewed

- **Price snapshot date:** 2026-11-03

- **Price snapshot time / timezone:** Regular-session close, America/New_York (including exchange half-days)
- **Competitor / analyst-Q&A audit:** 2026-10-28; original operating, price and valuation snapshots retained.

## What's Changed Since Previous Review

**Current Review:** 2026-10-28

**Previous Review:** 2026-10-21 (comparison refresh; fundamental review preserved from 2026-10-20)

**Update Trigger:** Competitor relevance and analyst-Q&A correction

| Area | Previous View | Current View | Investment Impact |
|---|---|---|---|
| Competition | Preceding operating and comparable-company classifications | Company-specific rivals reviewed; relevant comparisons retained | Corrects the competitive comparison; does not by itself re-underwrite the valuation |
| Analyst questions | Prior source-linked Q&A summaries | Complete questions and sentence-form management answers; all 12 existing rows retained | Improves readability while preserving the recorded exchange meaning |
| Valuation and scores | Approved operating/price snapshots, scenarios, scores and decisions | Preserved | No price refresh, rerank or change to valuation assumptions in this correction pass |

**Thesis:** No new fundamental thesis determination is made in this correction pass. The prior investment decision is preserved; the corrected competitive scope should govern the next substantive review.

## Investment Snapshot

| Metric | Current View |
|---|---|
| Price Snapshot | $20.17 — 2026-11-03 regular-session close, America/New_York |
| Rating / Zone Status | Hold / Watch |
| Bear / Base / Bull Fair Value | $9.43 / $25.67 / $46.43 |
| Scenario Probabilities | 30% / 50% / 20% |
| Probability-Weighted Fair Value | $24.95 |
| Probability-Weighted Expected Return | +23.7% |
| Bear-Case Return | -53.2% |
| Strong Buy Zone | ≤ $10.38 |
| Buy Zone | >$10.38–$19.96 |
| Avoid Chasing Above | > $27.72 |
| Quality Score / Tier | 61.9 / Tier C |
| Opportunity Score / Rank | 58.7 / #28 of 76 |
| Risk Level | High |
| Tracking / Ownership | Primary Watchlist / Not Owned |

**Decision rationale:** PRCT offers potentially attractive upside at the analyzed price, but deserves a much higher risk premium than an established, profitable surgical robotics company. Its Aquablation technology and procedure-driven recurring revenue opportunity are compelling, yet weak utilization of older systems, declining free cash flow and persistent operating losses keep this a speculative rather than high-conviction Buy.

## Investment Thesis

PROCEPT BioRobotics develops robotic surgical systems that treat benign prostatic hyperplasia (BPH), commonly called an enlarged prostate. Its Aquablation technology offers a potentially compelling alternative to conventional prostate surgery, particularly because it aims to deliver durable symptom relief while preserving urinary continence and sexual function.

The attractive part of the business is not simply selling robots. It is building a large installed base of robotic systems that generate recurring revenue every time a hospital performs a procedure.

**The investment opportunity comes from the growing divergence between clinical adoption and investor confidence.** PRCT's share price has fallen dramatically, but procedure volumes continue to grow. The concern is that system sales, pricing and operating expenses are not yet translating that growth into improving profitability.

The central question is whether PROCEPT can turn its promising technology into a profitable, defensible medical-device franchise before competition, reimbursement pressure or cash consumption undermine shareholder returns.

My initial assessment is that PRCT offers potentially attractive upside at current prices, but deserves a substantially higher risk premium than an established, profitable surgical robotics company.

### What the Market May Be Mispricing

First, PROCEPT's share price has been heavily repriced even as its clinical treatment opportunity and HYDROS rollout remain intact. Second, consumables may become the main economic driver rather than lumpy initial equipment purchases if system utilization matures. Third, if HYDROS changes mature-site productivity and commercial spending eventually scales, operating leverage could improve substantially.

The counterargument is equally important: the market may correctly be pricing a lasting utilization problem rather than a temporary execution setback.

## Business Overview

BPH occurs when the prostate enlarges and obstructs urine flow, potentially causing frequent urination, interrupted sleep, a weak urinary stream and incomplete bladder emptying. Medicines help some patients, but others eventually need a procedure.

PROCEPT offers **Aquablation**, using real-time ultrasound imaging, robotic planning and a controlled waterjet to remove obstructive prostate tissue. Unlike conventional thermal ablation techniques, the tissue-removal portion of Aquablation does not rely on heat.

Its primary products are the legacy AquaBeam system and the newer HYDROS platform, which incorporates enhanced imaging, planning and workflow capabilities.

| Segment / Brand / Business Unit | Role | Revenue / Growth | Economics / Position | Strategic Takeaway |
|---|---|---|---|---|
| Robotic systems (HYDROS and AquaBeam) | Hospitals purchase or lease capital equipment | ~$29.1M U.S. system revenue in Q2 2026 | Creates an installed base; revenue is lumpy | Placements are valuable to the extent they produce utilization |
| Single-use handpieces and other consumables | Disposable supplies for procedures | ~$48.4M U.S. revenue in Q2 2026 | Recurring, procedure-linked sales | Largest domestic revenue stream in Q2; long-term core economics |
| Service and accessories | Maintenance and related equipment | Included in related revenue categories | Supports customer relationships | Adds retention and service economics |
| International | Systems, disposables and services outside the U.S. | Growing opportunity; smaller current business | Geographic expansion | Long-duration runway |

PROCEPT sells into hospitals, while urologists influence usage and patient selection. It spends on clinical studies, surgical education, sales teams and commercial programs to expand the installed base and procedure volumes.

### Business Takeaway

The most valuable part of the franchise is the recurring revenue opportunity. Installed systems create a customer relationship; procedure volume determines how much that relationship ultimately earns. A robot performing 100 procedures annually has a very different economic value from one performing 30.

## Industry, TAM & Market Share

PROCEPT targets a substantial established market rather than creating an entirely new category. BPH is common among aging men, and surgical treatment is already reimbursed and widely practiced.

The company estimated approximately **400,000 U.S. BPH procedures in 2024**. It performed roughly **43,300 U.S. Aquablation procedures in 2025**, implying penetration in the neighborhood of 11% when compared with that prior-year market estimate. Because periods and market definitions differ, this illustrates scale, not a precise audited market-share figure.

The opportunity is substantial even without assuming growth in patients seeking surgery. PROCEPT can gain share from TURP, laser enucleation, water-vapor therapy and other minimally invasive procedures.

| Year | U.S. Aquablation procedures |
|---|---:|
| 2023 | ~16,500 |
| 2024 | ~27,800 |
| 2025 | ~43,300 |
| 2026E (company guidance midpoint) | ~55,000 |

The 2026 midpoint implies about 27% growth over 2025, materially slower than the approximately 56% procedure growth in 2025.

### Market-Share Analysis

A consistently defined, comparable market-share dataset for all BPH treatment competitors was not available. Competitors sell fundamentally different procedural technologies; equating placements or manufacturer revenue with procedure share would be misleading. The following competitive-position view is more useful.

#### Competitive Scale / Position

| Company / Platform | Primary Position | Relative Scale | Growth Direction | Investment Relevance |
|---|---|---|---|---|
| PROCEPT / Aquablation | Robotic tissue removal | Smaller installed base; fast expansion | Growth continues but slows in 2026 | Upside depends on adoption and utilization |
| TURP and laser procedures | Established surgical standards | Deeply embedded in hospitals | Mature | Proven procedural alternatives |
| Boston Scientific / Rezūm | Water-vapor therapy | Diversified large device manufacturer | Established | Less invasive alternative |
| Teleflex / UroLift | Prostatic urethral lift | Established minimally invasive platform | Established | Competes for physician and patient selection |
| Olympus / iTind and instruments | Temporary implant and urology instruments | Extensive urology relationships | Established | Distribution and physician familiarity |

### Industry Takeaway

A large market and favorable clinical momentum support continued growth, but **total market size is not realizable demand**. Hospital budgets, surgeon preferences, patient selection, reimbursement and established alternatives constrain adoption.

## Customer Economics

In Q2 2026, new HYDROS systems sold for approximately **$495,000** on average, while single-use handpieces averaged **$3,550**. At that handpiece price, 100 procedures generate about $355,000 in annual gross handpiece sales before discounts, product costs and other expenses. This illustrates why utilization can ultimately matter more than the initial capital sale.

The company delivered **65 U.S. HYDROS systems** in Q2 2026: 50 new installations, 14 replacements and one lease. Replacements strengthen the installed base technologically but do not add customer sites.

The central concern is that older AquaBeam systems have experienced weaker procedure utilization, and management has not fully identified the cause. HYDROS systems are performing materially better, but the difference may reflect technology, physician enthusiasm, customer selection or installation age.

### Customer-Economics Takeaway

The recurring revenue model is attractive only if systems maintain high and growing procedure volumes. The most useful operating measure is **same-site procedure growth separated between mature AquaBeam and HYDROS sites**, not total procedures divided by every installed robot.

## Competitive Landscape & Moat

### Competitive Landscape

| Competitor | Market Share | Positioning | Advantages vs. Company | Disadvantages vs. Company | Current Direction |
|---|---|---|---|---|---|
| Traditional TURP / HoLEP | Not comparable | Established surgical standards | Familiar, effective procedures; surgeon training and hospital equipment | Robotic waterjet may offer more standardized treatment and a favorable functional-outcome profile | Mature standard of care |
| Boston Scientific / Rezūm | Not disclosed comparably | Water-vapor minimally invasive therapy | Less invasive approach and large sales organization | Tissue removal may offer different efficacy/durability for selected patients | Established alternative |
| Teleflex / UroLift | Not disclosed comparably | Prostatic urethral lift | Less invasive, often office-oriented workflow | Aquablation may address more substantial obstruction | Established alternative |
| Olympus / iTind and instruments | Not disclosed comparably | Temporary implant and urologic tools | Urology relationships, scale and infrastructure | Integrated robotic waterjet platform is differentiated | Established alternative |

Clinical support is meaningful. A May 2026 AUA guideline update strengthened Aquablation's recommendation for prostates of 30–80 mL and recognized its potential use for 80–150 mL prostates. WATER III clinical findings support attractive functional outcomes against laser treatment, although short follow-up and study-design limits constrain generalization.

### Moat Assessment

The main moat sources are proprietary technology, clinical evidence, regulatory authorization, physician training, distribution relationships and the growing installed base. Switching costs exist, but hospitals can support multiple BPH modalities and surgeons do not have to use Aquablation exclusively.

**Moat direction: Strengthening, but not proven durable.**

### Competitive Takeaway

HYDROS and improved guidelines reinforce PROCEPT's clinical differentiation, while weaker legacy utilization challenges confidence in long-term customer retention and procedure intensity.

## Financial Profile

### Historical Financials

Financial reporting periods follow the issuer's fiscal year: completed FY rows plus standalone current-year quarters and cumulative H1/9M for FY2026. Revenue, FCF and SBC are flows; cash is a period-end balance. FCF = operating cash flow minus property/equipment capex from SEC company facts; quarterly FCF after Q1 and any quarterly SBC derived from YTD are visibly marked. Missing values are N/D, not zero. Unit: USD millions. Data extracted from SEC-tagged filings as of 2026-11-07. Company-specific FCF definitions and acquisition effects may require further reconciliation.

| Period | Revenue | Growth | Gross Margin | Operating Margin | FCF | FCF Margin | SBC | Diluted Shares | Cash | Debt |
|---|---:|---:|---:|---:|---:|---:|---:|---:|---:|---:|
| FY2023 | $136.2 | 81.6% | 52.2% | −80.2% | −$133.2 | −97.8% | $19.1 | 47.3 | $257.2 | ~$52.0 |
| FY2024 | $224.5 | 64.8% | 61.1% | −43.0% | −$103.6 | −46.2% | $31.8 | 52.1 | $333.7 | $51.5 |
| FY2025 | $308.1 | 37.2% | 63.7% | −33.7% | −$58.3 | −18.9% | $47.6 | 55.5 | $286.5 | $51.6 |
| Q1 FY2026 | $83.132 | N/D | 64.9% | -39.2% | −$41.041 (derived: CFO - capex) | -49.4% | $13.072 | 56.511 | $245.641 | N/D |
| Q2 FY2026 | $94.498 | N/D | 66.0% | -29.0% | −$22.204 (derived: current YTD - prior YTD) | -23.5% | $14.534 (derived: current YTD - prior YTD) | 57.067 | $227.914 | N/D |
| H1 FY2026 | $177.631 | N/D | 65.5% | -33.8% | −$63.245 (derived: CFO - capex) | -35.6% | $27.606 | 56.79 | $227.914 | N/D |
| Q3 FY2026 | $98.291 | N/D | 66.3% | -27.9% | −$9.652 (derived: current YTD - prior YTD) | -9.8% | $15.08 (derived: current YTD - prior YTD) | 57.326 | $218.369 | N/D |
| 9M FY2026 | $275.922 | N/D | 65.8% | -31.7% | −$72.897 (derived: CFO - capex) | -26.4% | $42.686 | 56.971 | $218.369 | N/D |

#### Supplemental historical reporting context (retained)

#### Supplemental historical reporting context (retained)

#### Supplemental historical reporting context (retained)

Diluted shares equal basic weighted-average shares during loss periods.

### Financial Takeaways

**Revenue growth is slowing considerably.** Growth fell from 65% in 2024 to 37% in 2025 and approximately 20% in H1 2026. Full-year guidance of $390M–$410M implies second-half acceleration, which is not guaranteed.

**Gross margins are improving over the long term, but Q2 quality was weaker than the headline suggests.** Q2 2026 reported gross margin around 66% included a $2.9M one-time tariff refund. Without that refund, implied margin was roughly 63%, below the reported figure and prior-year level.

**Operating leverage has stalled.** First-half operating margin near negative 34% resembles FY2025. Revenue growth is not yet sufficiently exceeding commercial and development spending.

**Cash burn is the most significant financial concern.** H1 FCF deteriorated to −$63.2M from −$36.7M in H1 2025. Accounts receivable and inventory grew, contributing to working-capital consumption.

**SBC is material.** It equaled approximately 15.5% of revenue in both FY2025 and H1 2026. Excluding it from adjusted EBITDA does not remove the impact of potential dilution.

At June 30, PROCEPT held $227.9M unrestricted cash and roughly $51.7M long-term debt. In September 2026, loan maturity was extended from October 2027 to October 2028. This improves flexibility, but sustained cash consumption would reduce the buffer.

**Financial direction: Mixed, leaning negative.** Gross-margin progress and revenue scale are positives; dependable cash generation remains unproven.

## Management & Capital Allocation

CEO Larry Wood has helped commercialize HYDROS and expand clinical adoption. Management is investing in physician training, commercial reorganization, consumer awareness and clinical indications.

The 2026 procedure-guidance reduction from 60,000–64,000 to 54,000–56,000 is significant. Management also increased expected adjusted EBITDA losses while acknowledging incomplete understanding of the legacy AquaBeam utilization decline.

The central allocation question is whether commercial spending creates enough incremental procedures. Building a larger sales force without improving same-site demand would be poor capital productivity.

Securities class-action litigation filed in July 2026 adds governance and disclosure risk. Allegations concerning handpiece sales, procedures, discounting and guidance remain **unproven**; no adverse finding should be presumed. The allegations overlap with key operating metrics investors should scrutinize.

### Management Takeaway

Management has demonstrated product and placement execution. Guidance reliability and sales-spending efficiency must improve before higher confidence in its capital allocation is warranted.

## Valuation

### Current Valuation

| Metric | Value |
|---|---:|
| Price Snapshot | $20.17 — 2026-11-03 regular-session close, America/New_York |
| Market Capitalization | ~$1.05B |
| Enterprise Value | ~$0.90B, including lease adjustments |
| Trailing Revenue | ~$337M |
| EV / Trailing Revenue | ~2.7× |
| EV / 2026 Guided Revenue | ~2.2× (at $400M midpoint) |
| P/E | Not meaningful — losses |
| FCF Multiple | Not meaningful — negative FCF |
| Shares Outstanding | ~57.3M |
| June 2026 Net Cash, Excluding Leases | ~$176M |

Only the price row is refreshed here. Other quoted valuation statistics retain their earlier source dates and definitions.

### Comparable Company Analysis

| Company | Relevance | Public / Private | EV / Sales | P/E | Growth / Margin / Risk Context |
|---|---|---|---:|---:|---|
| **PROCEPT BioRobotics** | Subject company | Public | **~2.7×** | N/M | High growth; negative operating income and FCF |
| Boston Scientific | Rezūm direct operating competitor; diversified valuation anchor | Public | ~3.7× | N/A — not used for comparison | Scaled profitable diversified medical device business |
| Teleflex | UroLift direct operating competitor; diversified valuation anchor | Public | ~3.6× | N/A — not used for comparison | Established business with lower growth |
| Olympus | Urologic equipment competitor; secondary valuation anchor | Public | ~1.9× | N/A — not used for comparison | Much larger, profitable, slower-growing diversified business |

**Comparable takeaway:** The peer comparison offers perspective, not a direct valuation formula. PROCEPT's discount to some diversified device manufacturers looks attractive, but those companies generate profits and have more diversified revenue streams. PRCT could earn a premium if HYDROS becomes a dependable, profitable growth platform; conversely, its multiple could fall further if procedures weaken while losses persist.

### Valuation Scenarios

The primary method is a **2028 enterprise-value-to-revenue model**, discounted to the snapshot at 13% annually over two years. Each scenario incorporates estimated 2028 revenue, exit EV/sales, net cash and diluted shares. These are analyst assumptions, not company guidance.

| Scenario | Key Assumptions | Fair Value | Probability | Probability Rationale | Return From Price Snapshot |
|---|---|---:|---:|---|---:|
| **Bear** | 2028 revenue $450M; EV/sales 1.7×; net cash $30M; 66M diluted shares | **$9.43** | **30%** | Persistent utilization issues, inefficient spending or dilutive funding remain credible | -53.2% |
| **Base** | 2028 revenue $600M; EV/sales 3.25×; net cash $115M; 63M diluted shares | **$25.67** | **50%** | Continued slower growth plus improving operating economics is plausible | +27.3% |
| **Bull** | 2028 revenue $760M; EV/sales 4.6×; net cash $150M; 61.5M diluted shares | **$46.43** | **20%** | Strong HYDROS adoption and procedure momentum are possible but unproven | +130.2% |
| **Probability-Weighted** | Present value of scenario outcomes | **$24.95** | **100%** | 30% bear, 50% base, 20% bull | +23.7% |

Bear-case probability is substantial because utilization, commercial efficiency and cash conversion remain uncertain. Returns compare the present fair values with the October 19 price; they are not annualized forecasts.

### Valuation Takeaway

- **Primary valuation method:** 2028 EV/revenue scenario model discounted at 13% annually.
- **Cross-check methods:** Current EV/trailing sales, EV/guided 2026 sales and diversified medical-device peer EV/sales.
- **Key valuation dependencies:** Procedure utilization, 2028 revenue, sustainable margins, cash burn, net cash, exit multiple and fully diluted shares.
- **Valuation confidence / Risk Level:** High risk / low-to-moderate confidence; scenario outcomes are exceptionally wide.
- **Margin-of-safety conclusion:** Probability-weighted fair value ~$24.95 implies about 36.5% upside from $18.28, but the bear case loses 48.4%; this is a speculative Buy, not a high-confidence bargain.

Derived zones under the current methodology: Strong Buy **≤ $10.38**; Buy **>$10.38 through $19.96**; Hold / Watch **>$19.96 through $27.72**; Avoid **>$27.72**.

## Analyst Questions

The complete material August 4, 2026 earnings-call Q&A was reviewed in the research presented in chat; related follow-ups are consolidated.

| Analyst / Firm | Core Question | Management Response | Research Read-Through |
|---|---|---|---|
| Matthew O'Brien / Piper Sandler | How do system placements, replacements and recurring sales support 2026 revenue? | Management outlined expected system revenue, handpiece revenue and international contribution. | Capital sales offset some procedure weakness; mix needs monitoring. |
| Brandon Vazquez / William Blair | Why are older AquaBeam sites underperforming, and will the sales realignment fix them? | Management acknowledged incomplete understanding of the utilization decline, emphasizing stronger HYDROS performance. | **Most important unresolved question.** |
| Nathan Treybeck / Wells Fargo | Could reimbursement changes or alternative treatments hurt demand? | Management defended the clinical and economic positioning. | Reimbursement and competitive sensitivity remain material. |
| Vijay Kumar / Evercore | Why are systems selling when utilization is weaker? Are 2027 targets intact? | Management emphasized ASP strength; described earlier 2027 revenue expectations as broadly plausible but deferred formal guidance. | Revenue confidence exceeds utilization and margin visibility. |
| Stephanie Elghazi / BofA | What drove the ~7,000 reduction in procedure guidance? Why more spending? | Lower-end guidance assumes no material legacy-utilization recovery; investment includes direct-to-consumer programs in 18 markets. | Continuing weakness is partly reflected in guidance, but demand-generation ROI is unproven. |
| Richard Newitter / Truist | Can H2 acceleration and future operating leverage be delivered? | Management cited launch-team expansion, seasonality and expected profitability improvement. | Execution remains back-half weighted. |
| Stephens analyst | Do targets require big health-system orders or pulled-forward purchases? | Management said unusually large multi-system deals were not assumed. | Some reassurance on placement-guidance quality. |
| David Rescott / Baird | How do replacements affect pricing and margins? | Management discussed lower replacement ASPs and future recurring procedure revenue. | Upgrades can improve later utilization but affect near-term sales mix. |
| Mike Kratky / Leerink | Can management quantify the utilization uplift from new launch teams? | Management described encouraging outcomes but did not quantify an uplift. | Productivity improvement cannot yet be underwritten precisely. |
| Suraj Kalia / Oppenheimer | Why stress total procedure growth over per-system utilization? | Management emphasized sequential gains and stronger HYDROS accounts. | Aggregate growth can conceal mature-site weakness. |
| Josh Jennings / TD Cowen | Is consumer advertising generating measurable demand? | Management said patient-scheduling delays made quantification premature. | Advertising ROI is unproven. |
| Ryan Zimmerman / BTIG | Are H2 placements realistic and is demand being pulled forward? | Management reaffirmed ~210–220 new U.S. systems expected in 2026. | Requires a meaningful second-half placement ramp. |

### Analyst-Q&A Takeaway

Three unanswered questions stand out: why older systems are underused, whether commercial spending creates incremental procedures, and whether profitability expectations withstand lower utilization. Management did not dismiss the issue, but has not demonstrated a durable solution or provided metrics granular enough to independently verify one.

## Thesis Monitoring

| Driver | Current State | Positive Trigger / Catalyst | Negative Trigger / Falsifier | What It Changes |
|---|---|---|---|---|
| U.S. procedures | 2026 guidance 54k–56k | Growth reaccelerates, guidance stabilizes | More cuts or sustained deceleration | Revenue forecasts and multiples |
| Mature-site utilization | AquaBeam weakness unresolved | Same-site volumes recover | Persistent deterioration | Moat and recurring revenue assumptions |
| HYDROS adoption | Strong placements and utilization | High usage sustained as sites age | Usage falls as installed sites mature | Growth durability |
| Gross margin | ~65% full-year guidance | Sustainable gains excluding one-offs | Deteriorating margins on mix shift | Operating leverage |
| Cash flow | H1 FCF −$63M | Material reduction in burn and clear path to positive FCF | Continued cash drain or dilutive financing | Financial quality and fair value |
| Commercial efficiency | Higher spending; 18-market consumer pilot | Measurable patient activation and ROI | Rising customer-acquisition costs without utilization gains | Management score and margins |
| Clinical expansion | Better BPH guidelines; WATER IV investigational | Favorable evidence and approvals | Disappointing trials or delays | TAM and bull case |
| Governance / disclosure | Pending litigation | Clarity without adverse findings | Material adverse legal or reporting events | Confidence and valuation |

**Next checkpoint:** Expected Q3 2026 results on November 4, 2026. Focus on procedure volumes, mature-site trends, guidance and cash consumption rather than just headline revenue.

## Quality & Opportunity Scorecards

### Quality Score

| Component | Score | Weight | Weighted Contribution | Evidence |
|---|---:|---:|---:|---|
| Business durability and economics | 62 | 25% | 15.50 | Attractive consumables model, weak current profitability |
| Moat and competitive position | 67 | 25% | 16.75 | Differentiated technology, clinical evidence, meaningful competition |
| Growth runway and durability | 80 | 20% | 16.00 | Large BPH opportunity and substantial penetration runway |
| Financial quality and balance sheet | 43 | 15% | 6.45 | Cash runway but heavy burn and dilution |
| Management, governance and capital allocation | 48 | 15% | 7.20 | Product execution offset by guidance cuts and utilization uncertainty |
| **Quality Score** | **61.9** | **100%** | **61.90** | Tier C |

- **Quality Tier:** C
- **Speculative override:** None; commercial revenue and established clinical use exist. Investment remains high-risk.

### Opportunity Score

| Component | Raw Input | Normalized Score | Weight | Weighted Contribution |
|---|---|---|---|---|
| Quality | 61.9 | 61.9 | 30% | 18.6 |
| Probability-weighted upside | +23.7% | 97.4 | 35% | 34.1 |
| Bear-case downside | -53.2% | 0.0 | 20% | 0.0 |
| Risk / valuation confidence | 40 | 40.0 | 15% | 6.0 |
| **Opportunity Score** |  | **58.7** | **100%** | **58.7** |

- **Opportunity Rank:** #28 of 76
- **Zone Status:** Hold / Watch

## Portfolio Context

- **Tracking tier:** Primary Watchlist
- **Owned:** No
- **Tracking source of truth:** my_watchlist.md
- **Portfolio source of truth:** portfolio/holdings.md
- **Scoring independence:** Ownership, account, share count, position size and cost basis do not alter Quality Score, Opportunity Score, rank, rating, valuation or valuation zones.

## Investment Decision History

| Timestamp | Price | Rating | Zone Status | Buy Zone | Strong Buy Zone | Avoid Chasing Above | Base FV | P/W FV | P/W Return | Quality | Opportunity / Rank | Change / Rationale |
|---|---:|---|---|---|---|---|---:|---:|---:|---:|---:|---|---|
| 2026-10-20 22:54 ET | $18.28 | Buy — Speculative | Buy | >$10.38–$19.96 | ≤$10.38 | >$27.72 | $25.67 | $24.95 | +36.5% | 61.9 / Tier C | 59.9 / Unassigned | Initial analysis; repricing creates upside but legacy utilization, cash burn and execution risks are substantial |
| 2026-10-21 (America/New_York) | $18.82 | Buy — Speculative | Buy | >$10.38–$19.96 | ≤ $10.38 | > $27.72 | $25.67 | $24.95 | +32.6% | 61.9 | 59.6 / #25 | Common close and shared-universe rank; prior fundamental assumptions and zones preserved |

---

## Material Sources

| Source | Type | Date / Period | What It Supports |
|---|---|---|---|
| [2025 Form 10-K](https://www.sec.gov/Archives/edgar/data/1588978/000158897826000009/prct-20251231.htm) | Regulatory filing | FY2023–FY2025 | Company business, historical financials, industry size, risks |
| [Q2 2026 Form 10-Q](https://www.sec.gov/Archives/edgar/data/1588978/000158897826000030/prct-20260630.htm) | Regulatory filing | H1 2026 | Cash flow, balance sheet, operating trends, SBC |
| [Q2 2026 earnings release](https://ir.procept-biorobotics.com/news-releases/news-release-details/procept-biorobotics-reports-second-quarter-2026-financial) | Company IR | 2026-08-04 | System sales, procedures, revenue and guidance |
| [Q2 2026 earnings-call transcript](https://stockanalysis.com/stocks/prct/transcripts/657325-q2-2026/) | Transcript | 2026-08-04 | Management commentary, utilization, all material analyst Q&A |
| [AUA guideline update](https://ir.procept-biorobotics.com/news-releases/news-release-details/aua-guidelines-strengthen-recommendation-aquablationr-therapy) | Company IR / clinical guidelines | 2026-05-14 | Clinical positioning and applicable prostate sizes |
| [WATER III research](https://pubmed.ncbi.nlm.nih.gov/41638951/) | Clinical research | 2026 | Comparative surgical evidence |
| [Debt extension Form 8-K](https://www.sec.gov/Archives/edgar/data/1588978/000158897826000034/prct-20260923.htm) | Regulatory filing | 2026-09-23 | Loan maturity and liquidity |
| [PRCT market price history](https://www.marketbeat.com/stocks/NASDAQ/PRCT/chart/) | Market data | 2026-10-19 | Valuation price snapshot and market capitalization |
| [Boston Scientific valuation data](https://stockanalysis.com/stocks/bsx/financials/ratios/) | Market / comparable data | October 2026 | Secondary valuation anchor |
| [Teleflex valuation data](https://stockanalysis.com/stocks/tfx/financials/ratios/) | Market / comparable data | October 2026 | Direct operating competitor and valuation anchor |
| [Olympus investor relations](https://www.olympus-global.com/ir/) | Competitor company data | 2026 | Operating competitor and diversified valuation anchor |
| [PRCT common regular-close snapshot](https://stockanalysis.com/stocks/prct/history/) | Market data | 2026-10-20 16:00 EDT | Refreshed price, scenario returns and normalized Opportunity Score / shared rank |
| [SEC XBRL company facts — PRCT](https://data.sec.gov/api/xbrl/companyfacts/CIK0001588978.json) | Regulatory filing (as tagged) | FY2026, through 2026-09-30 | Current-year standalone-quarter and year-to-date source facts for FCF, SBC, revenue and other reported metrics |